Herantis Pharma Oyj reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net income was EUR 0.28 million compared to net loss of EUR 9.32 million a year ago. Basic earnings per share from continuing operations was EUR 0.02 compared to basic loss per share from continuing operations of EUR 0.64 a year ago.